Supernus Pharmaceuticals Inc (SUPN): Gregory S Patrick , VP, Chief Financial Officer of Supernus Pharmaceuticals Inc sold 3,395 shares on Jul 14, 2016. The Insider selling transaction was reported by the company on Jul 15, 2016 to the Securities and Exchange Commission. The shares were sold at $22.00 per share for a total value of $74,690.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 12, 2016, Padmanabh P. Bhatt (Sr. VP of IP, CSO) sold 30,762 shares at $16.49 per share price.On Dec 8, 2015, M James Barrett (director) sold 212,970 shares at $14.56 per share price.Also, On Jul 29, 2015, Stefan K.f. Schwabe (Executive Vice President R&D) sold 2,350 shares at $21.20 per share price.On Jul 16, 2015, Gregory S Patrick (VP, Chief Financial Officer) sold 6,217 shares at $20.00 per share price.
Shares of Supernus Pharmaceuticals Inc (SUPN) ended Friday, Jul 15, 2016 session in red amid volatile trading. The shares closed down -0.01 points or -0.05% at $21.84 with 3,28,791 shares getting traded. Post opening the session at $22.02, the shares hit an intraday low of $21 and an intraday high of $22.13 and the price vacillated in this range throughout the day. The company has a market cap of $1,079 M and the number of outstanding shares has been calculated to be 4,94,21,236 shares. The 52-week high of Supernus Pharmaceuticals Inc is $23.3008 and the 52-week low is $9.5101.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.